Preclinical characterization of a novel STING agonist, MK-1454

被引:0
|
作者
Cemerski, Saso [1 ]
Altman, Michael [1 ]
Bandi, Madhavi [1 ]
Chang, Wonsuk [2 ]
Chen, Yiping [1 ]
Cui, Long [1 ]
Cumming, Jared [1 ]
Dorosh, Lauren [1 ]
Flateland, Lauren [1 ]
Ma, Yanhong [1 ]
Javaid, Sarah [1 ]
Ho, Thu [3 ]
Kopinja, Johnny [1 ]
Laskey, Jason [1 ]
Minnihan, Ellen [1 ]
Price, Laura [3 ]
Mogg, Robin [3 ]
O'Donnell, Gregory [3 ]
Pan, Bo-Sheng [1 ]
Perera, Samanthi [1 ]
Piesvaux, Jennifer [1 ]
Presland, Jeremy [1 ]
Rakhilina, Larissa [1 ]
Schroeder, Gottfried [1 ]
Slavonic, Michael [1 ]
Smock, Steven [1 ]
Trotter, Benjamin Wesley [1 ]
Wyss, Daniel [2 ]
Zhao, Qing [4 ]
Zhao, Shuxia [1 ]
Sadekova, Svetlana [5 ]
Yu, Ying [5 ]
Khilnani, Anuradha [4 ]
Tse, Archie [4 ]
机构
[1] Merck Res Labs, Boston, MA USA
[2] Merck Res Labs, Kenilworth, NJ USA
[3] Merck Res Labs, West Point, PA USA
[4] Merck Res Labs, Rahway, NJ USA
[5] Merck Res Labs, Palo Alto, CA USA
来源
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
O31
引用
收藏
页数:2
相关论文
共 50 条
  • [21] TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
    Cunniff, Elizabeth Carideo
    Sato, Yosuke
    Mai, Doanh
    Appleman, Vicky A.
    Iwasaki, Shinji
    Kolev, Vihren
    Matsuda, Atsushi
    Shi, Judy
    Mochizuki, Michiyo
    Yoshikawa, Masato
    Huang, Jian
    Shen, Luhua
    Haridas, Satyajeet
    Shinde, Vaishali
    Gemski, Chris
    Roberts, Emily R.
    Ghasemi, Omid
    Bazzazi, Hojjat
    Menon, Saurabh
    Traore, Tary
    Shi, Pu
    Thelen, Tennille D.
    Conlon, Joseph
    Abu-Yousif, Adnan O.
    Arendt, Christopher
    Shaw, Michael H.
    Okaniwa, Masanori
    CANCER RESEARCH COMMUNICATIONS, 2022, 2 (06): : 489 - 502
  • [22] A novel STING agonist with systemic and durable anti-tumour activity
    Wang, Xiyuan
    Shen, Ancheng
    Zhang, Yan
    Chen, Xiaoxu
    Ding, Jian
    Zhang, Ao
    Geng, Meiyu
    Ding, Chunyong
    Xie, Zuoquan
    CLINICAL AND TRANSLATIONAL DISCOVERY, 2023, 3 (05):
  • [23] Initial preclinical development of a novel dual orexin receptor agonist
    Silvani, Alessandro
    Berteotti, Chiara
    Bastianini, Stefano
    Lo Martire, Viviana
    Alvente, Sara
    Matteoli, Gabriele
    Ciani, Elisabetta
    Trazzi, Stefania
    Medici, Giorgio
    Plazzi, Giuseppe
    Zoccoli, Giovanna
    JOURNAL OF SLEEP RESEARCH, 2024, 33
  • [24] Immune checkpoint inhibition improves antimyeloma activity of bortezomib and STING agonist combination in Vk*MYC preclinical model
    Sokolowska, Olga
    Rodziewicz-Lurzynska, Anna
    Pilch, Zofia
    Kedzierska, Hanna
    Chlebowska-Tuz, Justyna
    Sosnowska, Anna
    Szumera-Cieckiewicz, Anna
    Sokol, Kamil
    Barankiewicz, Joanna
    Salomon-Perzynski, Aleksander
    Ciepiela, Olga
    Lech-Maranda, Ewa
    Golab, Jakub
    Nowis, Dominika
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (05) : 1563 - 1572
  • [25] MK-801, NOVEL GLUTAMATE ANTAGONIST AND NEUROPROTECTIVE AGENT - PRECLINICAL DATA
    STAHL, S
    EPILEPSIA, 1987, 28 (04) : 448 - 449
  • [26] Immune checkpoint inhibition improves antimyeloma activity of bortezomib and STING agonist combination in Vk*MYC preclinical model
    Olga Sokolowska
    Anna Rodziewicz-Lurzynska
    Zofia Pilch
    Hanna Kedzierska
    Justyna Chlebowska-Tuz
    Anna Sosnowska
    Anna Szumera-Cieckiewicz
    Kamil Sokol
    Joanna Barankiewicz
    Aleksander Salomon-Perzynski
    Olga Ciepiela
    Ewa Lech-Maranda
    Jakub Golab
    Dominika Nowis
    Clinical and Experimental Medicine, 2023, 23 : 1563 - 1572
  • [27] Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas
    Luke, Jason J.
    Sweis, Randy F.
    Hecht, J. Randolph
    Schneider, Reva
    Stein, Mark N.
    Golan, Talia
    Yap, Timothy A.
    Khilnani, Anuradha
    Huang, Mo
    Zhao, Runchen
    Jemielita, Thomas
    Patel, Sandip Pravin
    CLINICAL CANCER RESEARCH, 2025, 31 (07) : 1233 - 1242
  • [28] Mechanistic insights into the antitumor activity of SB 11285-a novel STING agonist.
    Zhou, Shenghua
    Challa, Sreerupa
    Nair, Vishal
    Meher, Geeta
    Sheri, Anjaneyulu
    Gimi, Rayomand
    Padmanabhan, Seetharamaiyer
    Cleary, Dillon
    Suppiah, Leena
    Schmidt, Diane
    Khedkar, Santosh
    Iyer, Radhakrishnan
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (04) : 124 - 125
  • [29] A novel STING agonist for cancer immunotherapy and a SARS-CoV-2 vaccine adjuvant
    Wu, Jun-Jun
    Zhao, Lang
    Han, Bei-Bei
    Hu, Hong-Guo
    Zhang, Bo-Dou
    Li, Wen-Hao
    Chen, Yong-Xiang
    Li, Yan-Mei
    CHEMICAL COMMUNICATIONS, 2021, 57 (04) : 504 - 507
  • [30] 18F-FDG PET Visualizes Systemic STING Agonist-Induced Lymphocyte Activation in Preclinical Models
    Le, Thuc M.
    Lee, Hailey R.
    Abt, Evan R.
    Rashid, Khalid
    Creech, Amanda L.
    Liang, Keke
    Cui, Jing
    Cho, Arthur
    Wei, Liu
    Labora, Amanda
    Chan, Charlotte
    Sanchez, Eric
    Kriti, Kriti
    Karin, Daniel
    Li, Luyi
    Wu, Nanping
    Mona, Christine
    Carlucci, Giuseppe
    Hugo, Willy
    Wu, Ting-Ting
    Donahue, Timothy R.
    Czernin, Johannes
    Radu, Caius G.
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (01) : 117 - 123